Investor Presentation

130 Investor presentation First six months of 2022 North America Operations growth has accelerated DKK billion 3% North America Operations reported sales growth per therapy area 1% 60 57 3% 61 14% 67 24% 41 2018 2019 GLP-1 Insulin Other diabetes 2020 Obesity care 2021 H1 2022 Rare disease Growth at CER CER: Constant exchange rate Source: Quarterly company announcement NAO

View entire presentation